We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
- Authors
Hossain, Sultana Mehbuba; Ly, Kevin; Sung, Yih Jian; Braithwaite, Antony; Li, Kunyu
- Abstract
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma. However, over 50% of patients experience limited or no response to ICI therapy. Resistance to ICIs is influenced by a complex interplay of tumour intrinsic and extrinsic factors. This review summarizes current ICIs for melanoma and the factors involved in resistance to the treatment. We also discuss emerging evidence that the microbiota can impact ICI treatment outcomes by modulating tumour biology and anti-tumour immune function. Furthermore, microbiota profiles may offer a non-invasive method for predicting ICI response. Therefore, future research into microbiota manipulation could provide cost-effective strategies to enhance ICI efficacy and improve outcomes for melanoma patients.
- Publication
International journal of molecular sciences, 2024, Vol 25, Issue 18
- ISSN
1422-0067
- Publication type
Journal Article
- DOI
10.3390/ijms251810120